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A B S T R A C T
Secondary pulmonary hypertension is a frequent condition after heart valve surgery. It may significantly complicate
the perioperative management and increase patients’ morbidity and mortality. The treatment has not been yet completely
defined principally because of lack of the selectivity of drugs for the pulmonary vasculature. The usage of inhaled mil-
rinone could be the possible therapeutic option. Inodilator milrinone is commonly used intravenously for patients with
pulmonary hypertension and ventricular dysfunction in cardiac surgery. The decrease in systemic vascular resistance
frequently necessitates concomitant use of norepinephrine. Pulmonary vasodilators might be more effective and also de-
void of potentially dangerous systemic side effects if applied by inhalation, thus acting predominantly on pulmonary cir-
culation. There are only few reports of inhaled milrinone usage in adult post cardiac surgical patients. We reported 2 pa-
tients with severe pulmonary hypertension after valve surgery. Because of desperate clinical situation, we decided to use
the combination of inhaled and intravenous milrinone. Inhaled milrinone was delivered by means of pneumatic medica-
tion nebulizer dissolved with saline in final concentration of 0.5 mg/ml. The nebulizer was attached to the inspiratory
limb of the ventilator circuit, just before the Y-piece. We obtained satisfactory reduction in mean pulmonary artery pres-
sure in both patients, and they were successfully extubated and discharged. Although it is a very small sample of pa-
tients, we conclude that the combination of inhaled and intravenous milrinone could be an effective treatment of second-
ary pulmonary hypertension in high-risk cardiac valve surgery patient. The exact indications for inhaled milrinone
usage, optimal concentrations for this route, and the beginning and duration of treatment are yet to be determined.
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Introduction
Pulmonary hypertension is defined as a systolic pul-
monary artery pressure (PAP) of 35 mm Hg, or, alterna-
tively, as a mean PAP of 25 mm Hg at rest or 30 mm Hg
with exertion1.
Secondary pulmonary hypertension (PH) is a fre-
quent condition after heart valve surgery with the inci-
dence of severe PH in the range of 16–21 per cent2–4. It
may significantly complicate the perioperative manage-
ment and increase patients’ morbidity and mortality5.
The development of PH has long been considered an
important risk factor for poor outcome in patients under-
going valve replacement surgery. In patients with mitral
valve replacement (MVR) and severe PH the operative
mortality was in range from 15 to 31 per cent, reaching
even 61 per cent, when PAP was at systemic levels6. Re-
cently, several reports have demonstrated improved out-
come in patients with PH undergoing MVR, that was at-
tributed to better myocardial preservation, and improved
postoperative care. Nevertheless, this perioperative mor-
tality is still around 10 per cent. Almost all deaths were
attributed to persistent low cardiac output (CO) syn-
drome due to right ventricular failure3,4,7. However, the
mortality rate in patients with supra-systemic PAP was
as high as 28.5 per cent3.
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Regarding perioperative morbidity, about 40 per cent
of patients developed major complications including re-
operation for hemorrhage, stroke, respiratory failure,
myocardial infarction or >30 day hospitalization2,3,6.
All these facts emphasize the need for the effective
treatment of secondary PH after heart valve surgery. The
treatment of secondary PH has not been yet completely
defined, principally because of lack of selectivity of drugs
for the pulmonary vasculature4,8,9. The conventional the-
rapy consists of intravenous vasodilators (nitrates or
prostaglandins), but associated systemic hypotension with
increasing dosage, is obvious limiting factor10.
The possible therapeutic option could be the usage of
inhaled milrinone. Milrinone is an inodilator drug, i.e. it
is a non-sympathomimetic drug that increases myocar-
dial and vascular smooth muscle cyclic AMP concentra-
tions by inhibiting phosphodiesterase III enzymes, thus
modulating intracellular calcium levels and producing
increased myocardial contractility and systemic vasodi-
latation. It is commonly used intravenously for patients
with PH and ventricular dysfunction after cardiac sur-
gery11. The decrease in systemic vascular resistance fre-
quently necessitates use of norepinephrine together with
milrinone12.
Inhaled milrinone may be more effective and also de-
void of troublesome systemic side effects by acting pre-
dominantly on the pulmonary circulation. There are only
few reports of use of inhaled milrinone in adult post car-
diac surgical patients, with many unresolved questions –
strict indications for its usage, optimal drug concentra-
tion for this route, as well as time of beginning and dura-
tion of treatment10,13.
Methods
We reported 2 patients with severe PH after heart
valve surgery treated with inhaled milrinone, following
local Ethics Committee approval.
The patients were orotracheally intubated and venti-
lated by Evita XL ventilator (Draeger Medical, Luebeck,
Germany) in intermittent positive-pressure ventilation
(IPPV) mode. Tidal volumes and respiratory rates were
set to achieve end-tidal CO2 values between 4.0 and 4.5
kPa. Milrinone (Corotrope 10 mg/10 mL, Sanofi Aventis,
Paris, France) was delivered by means of pneumatic
medication nebulizer (Draeger Medical, Luebeck, Ger-
many), dissolved with 10 mililiters of saline, having final
concentration of 0.5 mg/mL. The nebulizer was attached
to the inspiratory limb of the ventilator circuit, just be-
fore the Y-piece. The use of nebulizer is possible in all
ventilation modes of Evita XL ventilator. The mean mass
diameter of droplets delivered was 6.2 mm, as stated by
the manufacturer, and they were delivered at a rate of 0.3
mL/min14,15. The duration of such treatment was approx-
imately 70 minutes. The minimal period between 2 mil-
rinone inhalations was set arbitrarily to 4 hours.
Intravenous vasoactive drugs were administered via
perfusors (Space, B. Braun Melsungen AG, Melsungen,
Germany), with following dose ranges (milrinone 0.5–0.75
mg/kg/min, nitroglycerine 1–3 mg/kg/min, dobutamine
2.5–10 mg/kg/min and amiodarone 900 mg/day).
The mean arterial pressure (MAP), systolic PAP, dia-
stolic PAP, mean pulmonary artery pressure (MPAP),
pulmonary artery wedge pressure (PAWP) and pulmo-
nary vascular resistance (PVR) values were analyzed at
four time points: before the beginning of the inhaled
milrinone treatment, at the end of inhaled milrinone
treatment, as well as 12 and 24 hours after the termina-
tion of inhaled milrinone. The hemodynamic values were
collected according to stored critical care charts data (in-
tervals of 60 minutes). CO was assessed before the in-
haled milrinone treatment and at the end of each prede-
termined period by a thermodilution technique using 5%




63-year old female underwent mitral and aortic valve
replacement (MVR+AVR), because of mitral and aortic
stenosis and insufficiency. Preoperatively, she had persis-
tent atrial fibrillation and chronic obstructive pulmo-
nary disease (Table 1). Her postoperative course was
complicated with severe PH. She was mechanically venti-
lated 3 days and could not be weaned. Her medications
were intravenous milrinone, nitroglycerine, and amioda-
rone. Despite high dosages of aforementioned drugs, her
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TABLE 1
CHARACTERISTICS OF PATIENTS RECEIVING COMBINED IN-
HALED AND INTRAVENOUS MILRINONE
Patient 1 2
Diagnosis AS + AI, MS + MI endocarditis, AI + MI
+ TI
EuroSCORE† 7 (6.55%) 20 (89.83%)
Surgery AVR + MVR AVR + MVR
Ventilator days 5 4
Imil 4 1
Inh (n) 3 3
Intravenous
drugs
MIL, NTGL, AMI D, MIL
Remarks COPD, AF preoperative heart
failure, endocarditis,
CVVHDF
MS – mitral valve stenosis, MI – mitral valve insufficiency, AS –
aortic valve stenosis, AI – aortic valve insufficiency, TI – tricus-
pid valve insufficiency, †EuroSCORE = EUROpean System for
Cardiac Operative Risk Evaluation23, standard and logistic va-
lue, AVR – aortic valve replacement, MVR – mitral valve repla-
cement, Imil – day (postoperative) of beginning the treatment
with inhaled milrinone, Inh (n) = number of applied inhalations
of milrinone, D – dobutamine, MIL – intravenous milrinone, AMI
– amiodarone, COPD – chronic obstructive pulmonary disease,
AF – atrial fibrillation, CVVHDF – continuous veno-venous he-
modiafiltration
PH was severe with systolic PAP reaching 80 mmHg and
MPAP in the range of 40–50 mmHg. Inhaled milrinone
was started on postoperative day 3, and repeated on post-
operative day 4. The hemodynamic values were improv-
ing, as shown in Table 2. During inhaled milrinone treat-
ment, there was a slight decrease in MPAP (–7.6 per
cent), but significant decrease of PVR (–42.5 per cent).
The hemodynamic data after the completion of inhaled
milrinone treatment were also favorable (Table 2). Twenty
four hours after the completion of the inhaled milrinone
treatment, there was no change in MPAP value regard-
ing baseline values, but there was a decrease in PVR
(–31.9 per cent) and increase in MAP (+16.2 per cent),
resulting in increase of MAP/MPAP ratio (+15.6 per
cent). On postoperative day 5 she was successfully wea-
ned from ventilator and extubated on postoperative day
6. The systolic PAP after extubation was in range of
55–60 mmHg, and MPAP of 30–35 mmHg. During the
following days, she was hemodinamically stable and was
discharged from the intensive care unit (ICU) on postop-
erative day 10 in good clinical condition.
Case 2
49-year old female was admitted to the cardiac sur-
gery ICU pre-operatively in very bad condition. She had
dyspnea, heart and renal failure, severe aortic insuffi-
ciency, as well as mitral and tricuspid insufficiency. Fif-
teen days before she had been admitted to the Cardiology
Department because of progressive dyspnea. Heart fail-
ure and endocarditis of aortic and mitral valve had been
found. Despite of desperate clinical conditions, the sur-
gery (AVR+MVR) was planned, after short pre-operative
stabilization in the ICU. Dobutamine and continous
veno-venous hemodiafiltration (CVVHDF) were started
pre-operatively (Table 1). On the day 5, she underwent
surgery. Despite high dosages of intravenous milrinone
and dobutamine after the surgery, she was unstable with
severe PH (systolic PAP occasionally reaching 90 mmHg
and MPAP >50 mmHg). Inhaled milrinone was started
as early as 6 hours postoperatively. The hemodynamic
data before, during and after the completion of the in-
haled milrinone treatment are shown in Table 2. During
inhaled milrinone treatment, PVR decreased by 40 per
cent, with minimal changes of other hemodynamic pa-
rameters. Twelve and 24 hours after the end of the in-
haled milrinone treatment, the pulmonary artery pres-
sures were significantly lower (–15.9 and –24.6 per cent,
respectively), but we were able to wean and extubate the
patient as late as on postoperative day 4. The systolic
PAP after extubation was in range of 48–55 mmHg, and
MPAP of 28–31 mmHg. On the following days inotropes
were gradually tapered, the patient was hemodinami-
cally stable. On postoperative day 10, the patient was
transferred to the Department of Cardiac Surgery in
good condition.
Discussion
We reported 2 patients with severe pulmonary hyper-
tension after heart valve surgery (Table 1). Because of
desperate clinical situation, we decided to use inhalation
milrinone. Although it is a very small sample of patients,
by combining multiple inhalations of milrinone (10 mg
milrinone per inhalation, concentration –0.5 mg/mL, rate
–0.15 mg/min) with intravenous milrinone (0.5–0.75
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* values are expressed in mmHg (MAP, MPAP, D-W) and dynes/s/cm5 (PVR), †average values for given time period (except D-W gradi-
ent, and PVR, measured immediately before the start of the inhaled milrinone treatment and furthermore once at the end of time pe-
riod),
‡ numbers in parentheses refer to percent change regarding baseline values of MAP, MPAP, MAP/MPAP ratio, and PVR, IM – inhaled
milrinone treatment, MAP – mean arterial pressure, MPAP – mean pulmonary arterial pressure, MAP/MPAP – ratio between mean
arterial and mean pulmonary pressure, D-W = gradient between pulmonary artery diastolic and wedge pressure, PVR = pulmonary
vascular resistance
mg/kg/min) we managed to reduce pulmonary artery pre-
ssures, PVR, and to increase MAP/MPAP ratio.
Secondary PH after heart valve surgery is undoubt-
edly still a considerable problem in the ICU, with the av-
erage mortality of 10 per cent and reaching almost 30 per
cent in the most severe cases. After preliminary reports
of d’Ambra and co-workers more than 20 years ago16, nu-
merous pulmonary vasodilators were applied, and recen-
tly new guidelines have been adopted from the American
College of Chest Physicians17. Despite these achieve-
ments, however, PH remains a serious, life-threatening
condition18.
There is only one article regarding inhaled milrinone
usage on intubated patients in the ICUs after adult car-
diac surgery. Haraldsson et co-workers conducted the
study in patients with pulmonary hypertension after cor-
onary artery bypass grafting (CABG) and orthotopic
heart transplantation, immediately after admittance to
the ICU. They used 3 different concentrations of milri-
none (0.25, 0.5 and 1 mg/mL), which were stepwise in-
creased in 10-minutes period. During the first part of the
study (9 patients) a decrease in pulmonary vascular re-
sistance (PVR) was found with a maximal effect (20%) at
the largest administered concentration without associ-
ated systemic effects. During the second part of the study
(11 patients), the inhaled milrinone was administered
concomitantly with inhaled prostaglandin I2 (iPGI2) and
there was an additional (8%) decrease in PVR. Interest-
ingly, 20 minutes after milrinone inhalation all patients’
values returned to baseline regarding all measured he-
modynamic values. They concluded that inhaled milri-
none alone or in combination with iPGI2 may present a
therapeutic option for marginal patients with pulmonary
hypertension and severe right-ventricular failure after
cardiac surgery10. Unlike our report, although the au-
thors had excellent protocol and included significant
number of patients, the duration of the impact of milri-
none on pulmonary hypertension was transient. Besides,
this cohort did not include patients after heart valve sur-
gery.
There are some other uses of inhaled milrinone in the
perioperative setting of cardiac surgery. Lamarche and
co-workers retrospectively analyzed 73 patients in 3-year
period receiving inhaled milrinone before or after car-
diopulmonary bypass (CPB). In this high-risk cohort
they found that inhaled milrinone was well tolerated,
and if administered pre-CPB it could help weaning from
CPB19. According to our opinion, it is difficult to predict
the onset of pulmonary hypertension after heart surgery
and we consider preventive use of inhaled milrinone as a
doubtful one.
In another study, inhaled aerosolized milrinone, given
for a short period (10 minutes) selectively dilated the pul-
monary vasculature in 18 heart transplant candidates
with elevated PAP, without producing systemic side ef-
fects. But, these patients were not mechanically venti-
lated and the dosage of milrinone was 2 mg dissolved in 3
mililiters of saline. Also, as distinguished from our case
reports, the authors used ultrasonic nebulizer and the
particle size ranges from 3 to 5 mm with this device20.
Inhaled milrinone is easy to deliver with modern ven-
tilators in the ICUs. It could be applied in every mode of
ventilation. The aerosol is derived synchronously with
the inspiration phase of flow and respiratory minute volume
is kept constant, as well as inspired oxygen fraction14.
In our patients the beginning of the treatment with
inhaled milrinone was as early as in the first postopera-
tive hours (case 2), and in case 1 on postoperative day 3,
after the failure of conventional therapies. Regarding the
hemodynamic variables after discontinuation of inhaled
milrinone, in patient 2 there was decrease of MPAP, while
in patient 1 there was a minimal change in MPAP values,
but MAP values were higher. As a result, the improved
MAP/MPAP ratio and considerably more favorable he-
modynamic conditions were achieved. Besides, we ob-
served the decrease in gradient between diastolic PAP
and PAWP in both patients (Table 2). Namely, in persons
with severe PH, diastolic PAP is often substantially hi-
gher than PAWP, while in normal circumstances they are
usually within 5 mmHg of one another21,22.
Along with small sample of patients, another limita-
tion of these reports could be the lack of comparison of
individual effects of either inhaled or intravenous mil-
rinone on pulmonary pressures, but it is not disputable
that combination of inhaled and intravenous milrinone
proved effective in these 2 patients. This beneficial he-
modynamic effect lasted even after the discontinuation
of inhaled milrinone, and the patients were successfully
extubated and discharged.
Although it is a very small sample of patients, we con-
clude that the combination of repeated inhaled (0.05 per
cent milrinone, at a nebulization rate of 0.15 mg/min)
and continuous intravenous milrinone (dose range 0.5–0.75
mg/kg/min) could be an effective treatment of secondary
pulmonary hypertension in high-risk cardiac valve sur-
gery patient. Optimal concentration for this route, the
time of beginning and duration of treatment are yet to be
determined.
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KOMBINACIJA INHALIRAJU]EG I INTRAVENSKOG MILRINONA U LIJE^ENJU PLU]NE
HIPERTENZIJE NAKON KIRURGIJE SR^ANIH ZALISTAKA
S A @ E T A K
Sekundarna plu}na hipertenzija je relativno ~esta nakon kirur{kog zahvata na sr~anim zaliscima. Ona mo`e zna-
kovito komplicirati perioperacijski period, te pove}ati pobol i smrtnost operiranih bolesnika. Na~in lije~enja ovog stanja
nije posve definiran, poglavito zbog manjka selektivnih lijekova za plu}ni krvo`ilni sustav. Uporaba inhaliraju}eg mil-
rinona mogla bi biti jedna od terapijskih mogu}nosti. Milrinon, lijek iz skupine inodilatatora, uglavnom se koristi intra-
venski kod bolesnika s plu}nom hipertenzijom i poreme}enom funkcijom klijetki nakon kardiokirur{kih zahvata. Pad
sustavnog vaskularnog otpora, a koji izaziva ovaj u~inkoviti lijek, obi~no zahtijeva istodobnu uporabu noradrenalina.
Smatra se da bi plu}ni vazodilatatori bili u~inkovitiji, a samim tim i bez potencijalno opasnih sustavnih nuspojava, kad
bi se primjenjivali inhalacijom, a na taj na~in bi mogli djelovati poglavito na plu}ni krvotok. U literaturi postoji svega
nekoliko izvije{}a o uporabi inhaliraju}eg milrinona u poslijeoperacijskoj skrbi kardiokirur{kog bolesnika, a uz jo{ uvi-
jek veliki broj nerije{enih pitanja – to~no definirane indikacije, vrijeme po~etka i trajanja lije~enja, te optimalne koncen-
tracije lijeka za ovaj na~in davanja. Ovdje smo opisali tijek lije~enja 2 bolesnika s te{kom plu}nom hipertenzijom nakon
zahvata na sr~anim zaliscima. Zbog uznapredovalog pogor{anja klini~kog stanja bolesnika, odlu~ili smo se u lije~enje
uklju~iti kombinaciju inhaliraju}eg i intravenskog milrinona. Milrinon, otopljen u fiziolo{koj otopini 0,5 mg/mL, je
davan pomo}u pneumatskog raspr{iva~a. Raspr{iva~ je bio priklju~en na inspiracijski krak ventilacijskog kruga, nepo-
sredno do Y-zavr{etka. Postigli smo zadovoljavaju}e smanjenje plu}nog tlaka u oba bolesnika, te su oba uspje{no ekstu-
birana i otpu{tena iz Jedinice intenzivnog lije~enja. Iako se radi o vrlo malom uzorku bolesnika, na{ je zaklju~ak da bi
kombinacija inhaliraju}eg i intravenskog milrinona mogla biti u~inkovita u visokorizi~nih bolesnika sa sekundarnom
plu}nom hipertenzijom nakon kardiokirur{kih zahvata na sr~anim zaliscima. To~no definirane indikacije, optimalnu
koncentraciju za ovaj na~in dopreme lijeka, te po~etak i trajanje lije~enja treba utvrditi u kontroliranim randomizi-
ranim eksperimentima.
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